VX-661 (F508del CFTR Corrector): Atomic Insights and Benchmarks for Cystic Fibrosis Research

Executive Summary: VX-661 (also known as tezacaftor) is a clinically validated small-molecule corrector for the F508del variant of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, developed by Vertex Pharmaceuticals and available from APExBIO (product page). It facilitates proper folding and trafficking of the misfolded F508del-CFTR, partially rescuing its plasma membrane expression and function in human bronchial epithelial cells (Tedman et al., 2025). Combination therapy with the potentiator VX-770 (ivacaftor) and a cAMP agonist further enhances CFTR-mediated chloride conductance, achieving up to 25% of non-CF cell activity in vitro. VX-661 exhibits aqueous solubility of ≥24.3 mg/mL and is stable as a solid at -20°C, making it suitable for controlled research applications (APExBIO). Clinical studies demonstrate its efficacy at 10–150 mg daily over 28 days, improving lung function and sweat chloride levels in F508del homozygous or heterozygous CF patients (APExBIO).

Biological Rationale

Cystic fibrosis (CF) is caused by mutations in the CFTR gene, leading to defective chloride ion transport across epithelial surfaces (Tedman et al., 2025). The F508del mutation is the most prevalent, representing approximately 70% of CF alleles worldwide (Cystic Fibrosis Foundation). This deletion disrupts CFTR protein folding, resulting in endoplasmic reticulum (ER) retention and degradation by quality control systems (Tedman et al., 2025). Proper folding and trafficking of CFTR to the apical plasma membrane are essential for its function as a cAMP-regulated chloride channel. Small-molecule correctors like VX-661 address the folding defect, increasing the surface density and functional activity of F508del-CFTR. Endogenous chaperones such as calnexin modulate CFTR folding and affect responsiveness to corrector drugs, highlighting the importance of cellular proteostasis in therapeutic outcomes (Tedman et al., 2025).

Mechanism of Action of VX-661 (F508del CFTR corrector)

VX-661 is a small-molecule CFTR corrector targeting the misfolded F508del-CFTR protein. Its chemical name is 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide (APExBIO). VX-661 binds to the first and second nucleotide-binding domains (NBD1 and NBD2) of CFTR, stabilizing the protein and reducing its propensity for ER-associated degradation (Tedman et al., 2025). This action increases the number of CFTR molecules reaching the apical plasma membrane. VX-661 partially reverts folding and processing defects, restoring plasma membrane densities of ΔF508-CFTR in vitro. When combined with the potentiator VX-770, which enhances channel gating, and a cAMP agonist, the maximal chloride conductance of rescued F508del-CFTR approaches 25% of non-CF levels in primary human bronchial epithelial cells (Tedman et al., 2025). Notably, chronic VX-661 treatment followed by acute VX-770 exposure is more effective than co-administration, as VX-770 can partially antagonize correction by VX-661 when present during folding (Related Mechanistic Insights).

Evidence & Benchmarks

• VX-661 (3 μM, 24 h, 26°C) increases cell surface F508del-CFTR density by 2–3 fold in CFBE41o- cells (Tedman et al., 2025, source).
• Chronic VX-661 treatment plus acute VX-770 and cAMP agonist elevates chloride conductance to ~25% of non-CF cells in primary human bronchial epithelial monolayers (Tedman et al., 2025, source).
• Clinical trials show FEV1 improvement of 4–6% (absolute) and sweat chloride reduction by 6–10 mmol/L after 28 days at 100–150 mg doses in F508del homozygous or heterozygous CF patients (APExBIO).
• VX-661 is soluble at ≥24.3 mg/mL in water and ≥21.8 mg/mL in DMSO, but insoluble in ethanol; solid is stable at -20°C for long-term storage (APExBIO).
• Calnexin (CANX) is necessary for optimal pharmacological rescue by VX-661 in certain CFTR variants, especially those with low basal expression (Tedman et al., 2025, source).
• Loss of calnexin disrupts VX-661 sensitivity but does not always reduce CFTR activity, indicating decoupling of folding correction and function (Tedman et al., 2025, source).

Compared to "VX-661: Small-Molecule CFTR Corrector for Cystic Fibrosis...", this article provides updated quantitative data and clarifies the variant-specific role of calnexin in VX-661 response. For deeper mechanistic context, see this analysis, which our evidence extends by including recent benchmark results in primary human cells.

Applications, Limits & Misconceptions

VX-661 is used extensively in cystic fibrosis research to model pharmacological rescue of the F508del-CFTR folding defect in vitro and in vivo. It serves as a reference corrector in preclinical drug screening workflows with human bronchial epithelial cell lines (e.g., CFBE41o-) and patient-derived organoids. VX-661 is frequently combined with VX-770 to assess synergistic or antagonistic effects on chloride channel activity. Its use in theratyping studies aids in mapping CFTR variant responsiveness and guiding precision medicine (Tedman et al., 2025).

Common Pitfalls or Misconceptions

• VX-661 is not effective for CFTR mutations that do not involve folding or trafficking defects; gating mutations may require different modulators.
• Co-administration of VX-770 during folding (rather than post-correction) can reduce VX-661 efficacy due to negative allosteric effects (Mechanistic Insights).
• VX-661 is not approved or intended for diagnostic or therapeutic use in humans outside controlled clinical studies or protocols.
• Long-term stability is assured only for the solid form at -20°C; aqueous or DMSO solutions should not be stored for extended periods.
• Resistance or lack of response in specific CFTR variants may reflect calnexin dependency or other proteostatic factors not addressed by VX-661 alone (Tedman et al., 2025).

Workflow Integration & Parameters

VX-661 from APExBIO (SKU: A2664) is supplied as a solid and should be stored at -20°C (product page). Stock solutions can be prepared in DMSO (≥21.8 mg/mL) or water (≥24.3 mg/mL); ethanol is not recommended due to insolubility. Typical in vitro protocols use 3 μM VX-661 for 24 hours at 26°C in cell culture models. For functional assays, primary human bronchial epithelial cells or CFBE41o- monolayers are common, with subsequent acute application of VX-770 and cAMP agonist to assess maximal chloride conductance. Solutions should be freshly prepared, as long-term storage reduces activity. In clinical research, dosing regimens range from 10 to 150 mg orally per day over 28 days, with efficacy measured by lung function (FEV1) and sweat chloride levels (APExBIO). For advanced strategies in assay design and calnexin-dependent modulation, see this recent mechanistic review—this article updates with latest findings on calnexin's domain-specific impact.

Conclusion & Outlook

VX-661 (tezacaftor) is a cornerstone tool for the study and pharmacological rescue of F508del-CFTR in cystic fibrosis research. Its well-characterized mechanism, robust efficacy benchmarks, and defined storage/handling parameters make it a leading choice for CFTR correction workflows. Ongoing research aims to further delineate domain- and chaperone-specific responses, supporting development of next-generation correctors and personalized medicine strategies (Tedman et al., 2025). APExBIO provides high-quality VX-661 to enable reproducible, advanced research in this domain (APExBIO).